Fig. 6From: Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathwaysImmunofluorescence analysis of E-cadherin and β -catenin expression patterns of (a) SKBR3 and (b) ZR75 cells. Treatment with DA (5 µM) and BMS-202 (5 µM) for 48 h enhances the expression of E-cadherin in both cancer cell lines and promotes the translocation of E-cadherin and β-catenin from the cytoplasm to the cell membrane and its undercoat, respectively, in comparison with DA and BMS-202 alone as well as untreated cells. Cells were treated as described in the materials and methods sectionBack to article page